Effect of Magnesium Sulfate added to local anesthetic in the anesthesia for the arm

Magnesium Sulfate as adjunvant to Bupivacaine in Supraclavicular Brachial Plexus Block: is it effective? - a randomized double-blind clinical trial - This study does not have an acronym This study does not have an acronym

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-5ch9crp

Enrollment

Unknown

Registered

2021-08-04

Start date

2020-12-21

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Forearm Fracture

Interventions

Intervention: supraclavicular brachial plexus block with 30mL with one injection of 0.4% bupivacaine and 1% magnesium sulfate. Control: supraclavicular brachial plexus block with 30mL with one inject

D01.875.800.800.850.500

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ASA classification PS1 and PS2; over 18 years of age; submitted to upper limb surgery with indication of supraclavicular brachial plexus block

Exclusion criteria

Exclusion criteria: presença de lesão de nervo periférico; doença cardíaca, hepática ou renal; vigência de tratamento com bloqueador de canal de cálcio; presença de distúrbios de coagulação ou uso de anticoagulantes; presença de infecção no local de punção; uso prévio de opioides; dificuldade para compreender a EVA (Escala Visual Analógica); alergia a anestésicos locais ou sulfato de magnésio; gestação; peso corporal inferior a 40kg; falha total ou parcial do bloqueio sensitivo 35 minutos após a injeção; pósoperatório em unidade de terapia intensiva; necessidade intraoperatória de mudança da técnica anestésica devido a falha do plano anestésico

Design outcomes

Primary

Measure	Time frame
Onset defined as the time interval between the end of the injection of the anesthetic solution and the sensory loss to the Pinprick test in the last nerve region (sensitive dermatomes of the musculocutaneous, radial, ulnar, median nerves).;Compare the intensity of postoperative pain according to the VAS in the first 24h	—

Secondary

Measure	Time frame
Motor block onset time defined as the time between the end of the anesthetic solution injection and the identification of paresis or paralysis for the last nerve according to pre-defined motor tests for the musculocutaneous, radial, ulnar and median nerve.;Motor block duration measured from the beginning of the block until the digital movement resumes.;Duration of analgesia measured as time from the beginning of the sensory block until the 2-point increase in the visual analogue pain scale (VAS);Comparison of the proportion of rebound pain	—

Measure

Time frame

Motor block onset time defined as the time between the end of the anesthetic solution injection and the identification of paresis or paralysis for the last nerve according to pre-defined motor tests for the musculocutaneous, radial, ulnar and median nerve.;Motor block duration measured from the beginning of the block until the digital movement resumes.;Duration of analgesia measured as time from the beginning of the sensory block until the 2-point increase in the visual analogue pain scale (VAS);Comparison of the proportion of rebound pain

—

Countries

Brazil

Contacts

Public ContactLucas Chaves

lchaves@gmail.com+5516981915134

Outcome results

None listed

Source: REBEC (via WHO ICTRP)